Obagi Medical Unveils ALOHA Program to Launch Obagi® saypha® MagIQ™ – Pioneering the Largest Real-World Evaluation of a New Hyaluronic Acid Filler

Rhea-AI Summary

Obagi Medical (NASDAQ: WALD) launched the ALOHA (Aesthetic Leadership with Obagi Hyaluronic Acid) Program on January 21, 2026 to collect structured real‑world, practice‑focused evidence for the rollout of Obagi® saypha® MagIQ™. The product is described as the company's first FDA‑approved injectable hyaluronic acid filler with claimed features including high usable HA content on injection, consistent gel distribution, and predictable injection force and swelling profile. ALOHA will gather standardized injector and practice owner feedback to inform post‑launch education, scientific content, and broader adoption and is positioned to become the largest real‑world evaluation of a newly launched HA injectable.

Positive

• First FDA approval for Obagi’s injectable hyaluronic acid product
• ALOHA program establishes structured real‑world data collection across practices

Negative

• None.

News Market Reaction

+6.92%

2 alerts

+6.92% News Effect

+$14M Valuation Impact

$222M Market Cap

0.9x Rel. Volume

On the day this news was published, WALD gained 6.92%, reflecting a notable positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $14M to the company's valuation, bringing the market cap to $222M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Industry experience: 35+ years Market position: Top 10

2 metrics

Industry experience 35+ years Obagi Medical legacy in advanced skincare

Market position Top 10 Among Top 10 professional skin care brands in U.S. in 2024

Market Reality Check

Price: $1.82 Vol: Volume 37,975 vs 20-day a...

low vol

$1.82 Last Close

Volume Volume 37,975 vs 20-day average 66,453, indicating relatively light trading ahead of this news. low

Technical Price $1.59 is trading below the $2.14 200-day moving average, reflecting a prior downtrend.

Peers on Argus

Peers showed mixed moves: EWCZ -4.25%, ACU -0.65%, SKIN -2.7% declined while DSY...

Peers showed mixed moves: EWCZ -4.25%, ACU -0.65%, SKIN -2.7% declined while DSY +2.11% and GROV +1.59% gained, suggesting stock-specific factors for WALD.

Historical Context

5 past events · Latest: Nov 24 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 24	Earnings and update	Negative	-6.5%	Q2/H1 2025 results with large goodwill impairments and net loss.
Nov 16	Clinical data update	Positive	+4.2%	Positive HA filler trial data and Nu-Cil scalp serum interim results.
Nov 14	Asset sale & loan	Neutral	+0.0%	Sale of Obagi Japan trademark and new secured term loan facility.
Nov 12	Earnings timing	Neutral	+0.0%	Announcement of upcoming Q2 and Q3 2025 earnings release dates.
Oct 08	Product launch	Positive	+7.6%	Launch of Nu-Cil BioStim Scalp Serum with supportive clinical data.

Pattern Detected

Across the last five news events, share price reactions generally aligned with the perceived tone of the announcements, with positive product/clinical updates and negative earnings developments moving the stock accordingly.

Recent Company History

Over the past months, Waldencast reported Q2 and H1 2025 results with $66.8M in Q2 net revenue and a sizeable H1 net loss driven by goodwill impairments, which coincided with a -6.49% move. Obagi Medical has been a key growth engine, highlighted by FDA approval of Obagi saypha MagIQ and positive clinical data for HA injectables and Nu-Cil BioStim Scalp Serum, including a +7.58% reaction to the scalp serum launch. Balance sheet actions included an $82.5M Obagi Japan trademark sale and a new $225M term loan, framing today’s ALOHA program as part of ongoing brand and product development.

Market Pulse Summary

The stock moved +6.9% in the session following this news. A strong positive reaction aligns with pri...

Analysis

The stock moved +6.9% in the session following this news. A strong positive reaction aligns with prior responses to Obagi-branded launches, such as the +7.58% move on the Nu-Cil BioStim Scalp Serum announcement and the +4.23% gain on favorable injectable data. The ALOHA program supports Obagi saypha MagIQ’s market entry using real-world evidence, building on earlier FDA approval and clinical work. Investors would monitor how quickly practice adoption and supporting data emerge, as well as how this complements earlier balance sheet and strategic actions.

Key Terms

hyaluronic acid, injectable, fda-approved, pivotal trials, +1 more

5 terms

hyaluronic acid medical

"new hyaluronic acid (HA) filler with category-leading features"

A naturally occurring molecule that acts like a tiny sponge, holding water in skin, joints and eyes to keep tissues plump and lubricated. Investors track products containing hyaluronic acid because they power large markets—such as skincare, injectable fillers, eye drops and wound treatments—so demand, regulatory approvals, manufacturing capacity and raw-material costs can meaningfully affect a company’s sales and profit outlook.

injectable medical

"FDA-approved injectable hyaluronic acid (HA) filler with category-leading features"

A product described as an "injectable" is a medicine or vaccine formulated to be given by needle, syringe, or infusion rather than taken by mouth. For investors it matters because injectables often require specialized manufacturing, cold storage and trained staff to administer, which can raise costs, create supply-chain risks and form higher barriers to competitors—factors that influence a product’s price, market reach and long-term revenue potential.

fda-approved regulatory

"the company's first FDA-approved injectable hyaluronic acid (HA) filler"

FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.

pivotal trials medical

"captures insights beyond pivotal trials, informing post-launch education"

Pivotal trials are the large, definitive clinical studies designed to show whether a drug or medical device works and is safe enough for regulatory approval. Investors watch them like a final exam for a product: passing typically clears the way to sell the therapy and generate revenue, while failing can delay or block approval and sharply reduce a company's value.

clinical collaboration medical

"This structured clinical collaboration initiative accelerates aesthetic innovation"

An arrangement where a company teams up with hospitals, research centers, or other firms to conduct clinical research, share patient data, or combine technical and medical expertise. For investors, such collaborations can shorten development time, lower costs and risks, and provide outside validation of a therapy or diagnostic—think of it as two teams pooling players and playbooks to get to market faster and with more confidence in the result.

AI-generated analysis. Not financial advice.

Program Designed to Drive Real World, Practice Focused Evidence with Injectables & Skincare

NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced the launch of the ALOHA (Aesthetic Leadership with Obagi Hyaluronic Acid) Program. This structured clinical collaboration initiative accelerates aesthetic innovation through practice-led insights and will support the introduction of Obagi^® saypha^® MagIQ™ – the company's first FDA-approved injectable hyaluronic acid (HA) filler with category-leading features including high useable HA content upon injection, consistent gel distribution, and a predictable injection force and swelling profile¹.

“ALOHA reflects our commitment to launching innovation differently and supporting category growth,” said Drew Fine, U.S. General Manager, Professional Channel. “By gathering real-world data across diverse practice settings, we will demonstrate how Obagi^® saypha^® MagIQ™ and Obagi skincare can drive practice success and patient satisfaction. The program's inclusive design embodies our Aesthetics for All™ ethos and invites broad industry participation.”

The ALOHA program creates a platform for practices to integrate real-world clinical experience into the product lifecycle. Participants will incorporate Obagi^® saypha^® MagIQ™ into routine treatments and provide structured feedback via standardized surveys from injectors and practice owners. This authentic, practice-driven approach captures insights beyond pivotal trials, informing post-launch education, scientific content, and wider adoption. The program is expected to become the largest real-world evaluation of a newly launched HA injectable.

“We are thrilled to partner with our valued Obagi providers to introduce this MagIQ-al new injectable,” added Mr. Fine. “Practices interested in participating are encouraged to sign up or contact their Obagi representative for more details.”

For more information about ALOHA, visit https://obagi-professional.com

About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm^® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,² Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi Medical is available on the brand's website, https://www.obagi.com.

About Waldencast plc
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing its vision was the Business Combination. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: https://ir.waldencast.com.

Media Contact:
obagi@behrmancesa.com

Source: Waldencast plc

1. Puljic A, Frank K, Cohen J, Otto K, Mayr J, Hugh-Bloch A, Kuroki-Hasenöhrl, D. A Scientific Framework for Comparing Hyaluronic Acid Filler Crosslinking Technologies. Gels. 2025; 11(7):487
2. Among the Top 10 Professional Skin Care Brands in the U.S., According to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.).

FAQ

What did Obagi Medical announce on January 21, 2026 regarding WALD?

Obagi Medical announced the ALOHA program to support the launch of Obagi® saypha® MagIQ™, its first FDA‑approved HA filler.

What is Obagi® saypha® MagIQ™ and why is it notable for WALD shareholders?

It is described as Obagi's first FDA‑approved hyaluronic acid injectable with claimed features like high usable HA content and predictable swelling profile.

What will the ALOHA program do for practices using Obagi® saypha® MagIQ™?

Participants will integrate the filler into routine treatments and submit standardized injector and practice owner feedback to inform education and adoption.

How does Obagi describe the scale of the ALOHA evaluation for WALD’s new filler?

Obagi expects ALOHA to become the largest real‑world evaluation of a newly launched HA injectable.

Where can practices sign up for the ALOHA program announced by WALD?

Practices are asked to sign up or contact their Obagi representative and can find program information on the Obagi professional website.